» Articles » PMID: 24622040

Prevalence and Clinical Significance of Liver Function Abnormalities in Patients with Acute Heart Failure

Abstract

Aims: Liver pathology caused by cardiac dysfunction is relatively well recognized, however, its clinical importance has not been fully evaluated. The aim of this study was to assess the prevalence of liver function tests (LFTs) abnormalities and to identify associated factors mediating hepatic impairment in patients with acute heart failure (AHF).

Methods: The AHEAD (Acute Heart Failure Database) registry is a database conducted in 9 university hospitals and 5 regional health care facilities in the Czech Republic. From December 2004 to October 2012, the data of 8818 patients were included. The inclusion criteria for the database followed the European guidelines for AHF. Serum activities of all LFTs and total bilirubin were available in 1473 patients at the baseline.

Results: In patients with AHF, abnormal LFTs were seen in 76% patients (total bilirubin in 34%, γ-glutamyltransferase in 44%, alkaline phosphatase in 20%, aspartate aminotransferase in 42%, alanine aminotransferase in 35%). Patients with cardiogenic shock were more likely to have LFTs abnormalities compared to mild AHF and pulmonary oedema. LFTs abnormalities were strongly associated with AHF severity (left ventricular ejection fraction and NYHA functional class) and clinical manifestation. While hepatocellular LFTs pattern predominated in left sided forward AHF, cholestatic profile occurred mainly in bilateral and right sided AHF. Additionally, patients with moderate to severe tricuspid regurgitation had significantly higher prevalence of abnormalities in cholestatic LFTs.

Conclusions: Defining the LFTs profile typical for AHF plays an important role in management of AHF patients, since it may avoid redundant hepatic investigations and diagnostic misinterpretations.

Citing Articles

Prediction model and scoring system for in-hospital mortality risk in infants with heart failure aged 1-36 months: A retrospective case-control study.

Wei M, Shang S, Lv H, Liang X, Lu Y, Tang B Heliyon. 2025; 11(3):e42110.

PMID: 39927140 PMC: 11804692. DOI: 10.1016/j.heliyon.2025.e42110.


Hepatokines and their role in cardiohepatic interactions in heart failure.

Shouman W, Najmeddine S, Sinno L, Dib Nehme R, Ghawi A, Ziade J Eur J Pharmacol. 2025; 992:177356.

PMID: 39922419 PMC: 11862882. DOI: 10.1016/j.ejphar.2025.177356.


Cardiac Hepatopathy: New Perspectives on Old Problems through a Prism of Endogenous Metabolic Regulations by Hepatokines.

Berezin A, Obradovic Z, Berezina T, Boxhammer E, Lichtenauer M, Berezin A Antioxidants (Basel). 2023; 12(2).

PMID: 36830074 PMC: 9951884. DOI: 10.3390/antiox12020516.


Use and diagnostic value of liver enzyme tests in the emergency department and subsequent heart failure diagnosis: a retrospective cohort study.

Vasti E, Tabas J, Hoffman A, Pletcher M BMJ Open. 2022; 12(3):e055216.

PMID: 35354618 PMC: 8968565. DOI: 10.1136/bmjopen-2021-055216.


Liver dysfunction in idiopathic pulmonary arterial hypertension: prevalence, characteristics and prognostic significance, a retrospective cohort study in China.

Luo C, Wu W, Wu C, Qiu H, Yuan P, Jiang R BMJ Open. 2021; 11(9):e045165.

PMID: 34493501 PMC: 8424845. DOI: 10.1136/bmjopen-2020-045165.